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Abstract
Background: Argininosuccinate synthase (ASS)1 is a urea cycle enzyme that catalyzes the conversion of citrulline
and aspartate to argininosuccinate. Mutations in the ASS1 gene cause citrullinemia type I, a rare autosomal recessive
disorder characterized by neonatal hyperammonemia, elevated citrulline levels, and early neonatal death. Treatment for
this disease is currently restricted to liver transplantation; however, due to limited organ availability, substitute therapies
are required. Recently, extracellular vesicles (EVs) have been reported to act as intercellular transporters carrying genetic
information responsible for cell reprogramming. In previous studies, we isolated a population of stem cell-like
cells known as human liver stem cells (HLSCs) from healthy liver tissue. Moreover, EVs derived from HLSCs were
reported to exhibit regenerative effects on the liver parenchyma in models of acute liver injury. The aim of this
study was to evaluate whether EVs derived from normal HLSCs restored ASS1 enzymatic activity and urea production
in hepatocytes differentiated from HLSCs derived from a patient with type I citrullinemia.
Methods: HLSCs were isolated from the liver of a patient with type I citrullinemia (ASS1-HLSCs) and characterized by
fluorescence-activated cell sorting (FACS), immunofluorescence, and DNA sequencing analysis. Furthermore, their
differentiation capabilities in vitro were also assessed. Hepatocytes differentiated from ASS1-HLSCs were evaluated by
the production of urea and ASS enzymatic activity.
EVs derived from normal HLSCs were purified by differential ultracentrifugation followed by floating density gradient.
The EV content was analyzed to identify the presence of ASS1 protein, mRNA, and ASS1 gene. In order to obtain
ASS1-depleted EVs, a knockdown of the ASS1 gene in HLSCs was performed followed by EV isolation from these cells.
Results: Treating ASS1-HLSCs with EVs from HLSCs restored both ASS1 activity and urea production mainly through
the transfer of ASS1 enzyme and mRNA. In fact, EVs from ASS1-knockdown HLSCs contained low amounts of ASS1
mRNA and protein, and were unable to restore urea production in hepatocytes differentiated from ASS1-HLSCs.
Conclusions: Collectively, these results suggest that EVs derived from normal HLSCs may compensate the loss of ASS1
enzyme activity in hepatocytes differentiated from ASS1-HLSCs.
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Background
Citrullinemia type I is an autosomal recessive disorder
caused by a deficiency in argininosuccinate synthase
(ASS; common gene symbol alias: ASS1), an enzyme
that catalyzes the third reaction of the urea cycle [1].
Typical symptoms that characterize the disorder include
hyperammonemia, low plasma arginine levels, and ele-
vated levels of citrulline in the plasma and urine [2, 3].
Furthermore, accumulation of ammonia during the first
few days of life leads to poor feeding, vomiting, neuro-
psychiatric symptoms, and coma [2]. Current treatments
involve pharmacologic nitrogen scavenger therapy, life-
long protein restriction, and L-arginine supplementation
which are aimed towards symptomatic control. For pa-
tients that do not respond satisfactorily to these treat-
ments the only alternative is liver transplantation.
However, due to the limited availability of donor livers,
alternative treatments such as gene therapy are currently
under investigation [2].
Previously, we have isolated a population of stem cell-
like cells from the human liver known as human liver
stem cells (HLSCs) which not only express liver tissue-
specific markers, but also mesenchymal and embryonic
stem cell markers [4, 5]. Furthermore, under appropriate
cell culture conditions, HLSCs demonstrate in vitro dif-
ferentiation abilities as well as in vivo regenerative prop-
erties [4, 5]. For instance, under low gravity culture
conditions in the presence of hepatocyte growth factor
and fibroblast growth factor 4, HLSCs differentiate into
mature hepatocytes [4].
Over the past decade, stem cells have been studied ex-
tensively as a form of therapy due to their healing ability.
Several preclinical models have been developed out of
which a paracrine mechanism of action has been sug-
gested [6, 7]. In the midst of various paracrine mediators
identified, extracellular vesicles (EVs) have also been im-
plicated to play a role in the exchange of information
[8]. EVs are membrane bound particles secreted by cells
in the extracellular milieu. They are classified into two
main categories according to their size and subcellular
origin. Exosomes are smaller in size (30–100 nm) and
are released by exocytosis through the fusion of intracel-
lular multivesicular bodies with the plasma membrane.
Microvesicles, on the other hand, are larger (up to
1000 nm) and are shed by direct budding from the cell
plasma membrane [8]. Once secreted, these vesicles ei-
ther remain in the extracellular matrix close to the cell
of origin or disperse to other parts of the body through
the blood or lymphatic system allowing intercellular ex-
change of proteins, bioactive lipids, and nucleic acids.
As intercellular vehicles, EVs carry a variety of cargo.
For instance, Ratajczak et al. demonstrated that EVs de-
rived from embryonic stem cells may contribute towards
the reprogramming of hematopoietic progenitor cells
through the delivery of embryonic stem cell-derived
proteins and mRNA [9]. Subsequently, other studies
followed this up that showed that EVs derived from
adult cells also contained and transferred mRNAs and
miRNAs to target cells [10, 11].
The ability of EVs to reprogram as a consequence of
transferring RNAs has been demonstrated in different
tissues and pathologies [12]. For instance, we observed
that endothelial progenitor cell-derived EVs activated an-
giogenic pathways in recipient endothelial cells through
horizontal transfer of mRNA [11]. Moreover, in different
models of tissue injury, treatments with EVs derived
from mesenchymal stem cells have been reported to pro-
mote tissue regeneration [13–16]. We also observed that
the administration of EVs derived from HLSCs improved
the regeneration of liver in rats with a 70% hepatectomy
[17] and assisted in the overall recovery of mice in a
murine model of acute kidney injury [18].
In this study, we investigated whether EVs derived
from normal HLSCs had the ability to carry and transfer
wild-type ASS1 to mature hepatocytes differentiated
from ASS1-mutated HLSCs, thereby restoring enzyme
activity and urea production.
Methods
Isolation and culture of normal and mutated human liver
stem cells
A liver specimen from a 5-year-old citrullinemia type I
patient undergoing liver transplant was obtained under
written informed consent from the parents. The tissue
was provided anonymously according to the local tissue
banking protocol of discarded tissues (# 80911) ap-
proved by the University of Torino Ethics Board (Comi-
tato Bioetica di Ateneo).
Hepatocytes were isolated from the liver specimen (5–
20 g) by collagenase digestion following the same protocol
as for the isolation of normal HLSCs as described previ-
ously [5]. Briefly, isolated liver tissues were digested in liver
digest medium (Invitrogen, Carlsbad, CA, USA) at 37 °C.
The cell suspension obtained was filtered through a sterile
100-μm nylon mesh, centrifuged at 3000 g for 5 min and
subsequently washed in cold wash medium (Invitrogen).
The hepatocytes obtained were cultured in a medium
composed of three parts α-minimum essential medium
and one part endothelial cell basal medium-1 (3:1; Lonza,
Basel, Switzerland) supplemented with L-glutamine
(5 mM), penicillin (50 IU/ml), streptomycin (50 g/ml) (all
from Sigma-Aldrich, St. Louis, MO, USA), and 10% fetal
calf serum (FCS; Invitrogen). After a few days of culture
ASS1-HLSC clones were expanded and subsequently fro-
zen. Wild-type HLSCs were isolated from cryopreserved
normal human hepatocytes (hH) obtained from Cambrex
Bio Science, Verviers S.p.r.l. (Verviers, Belgium). hH were
also used as normal control of mature hepatocytes.
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Isolation of HLSC-derived EVs (HLSC-EVs)
Briefly, 2 × 106 HLSCs and shRNA ASS1 knockdown
HLSCs (HLSC shRNA-ASS1) were cultured in serum-
free Roswell Park Memorial Institute (RPMI) medium
for 18 h at 37 °C. The supernatant was centrifuged for
20 min at 3000 g to remove cell debris and apoptotic
bodies. This was followed by a two-step ultracentrifuga-
tion protocol whereby the supernatant was firstly centri-
fuged at 10,000 g (10 K) for 1 h at 4 °C to pellet the
10 K EV fraction and then a second ultracentrifugation
at 100,000 g (100 K) for 1 h at 4 °C to isolate the 100 K
EV fraction (Beckman Coulter Optima L-90 K, Fullerton,
CA, USA) [19]. Both the 10 K and 100 K fractions were
resuspended in RPMI supplemented with 1% dimethyl
sulfoxide (DMSO) and frozen at –80 °C for later use.
The viability of HLSCs at the time of EV collection was
97–99% as determined by trypan blue exclusion.
As suggested by Kowal et al. [20], an iodixanol (Opti-
prep from Sigma-Aldrich) floating separation protocol
was used to further purify the EV fractions from free
floating contaminating proteins and RNAs [21]. Briefly,
the pellets of EVs obtained after differential ultracentri-
fugation were directly resuspended in 500 μl 60% iodixa-
nol (Optiprep from Sigma-Aldrich) mixed with 0.25 M
sucrose and transferred to ultracentrifuge tubes (10.4-ml
polycarbonate centrifuge bottles; Beckman Instruments).
Subsequent gradients of iodixanol at 30%, 15%, and 5%
were then layered on top of the initial 60% EV-
iodixanol/sucrose preparation and the final volume ad-
justed to 10 ml by topping up with saline solution. The
tubes were then ultracentrifuged at 350,000 g for 1 h, 4 °
C, without braking in an Optima L-100 K ultracentrifuge
(Beckman Coulter) equipped with type 90Ti rotor. Fol-
lowing ultracentrifugation, the 15%, 30%, and 60% frac-
tions were recovered, diluted with phosphate-buffered
saline (PBS), and ultracentrifuged again at 100,000 g for
1 h. The pellet obtained was resuspended in RPMI sup-
plemented with 1% DMSO and either used fresh or
stored for subsequent studies under –80 °C conditions.
No difference in biological activity was observed be-
tween fresh and stored EVs.
In order to study the internalization of EVs by fluores-
cent microscopy, EVs were labeled with 1 μM Dil dye
(Thermo Fisher Scientific, Waltham, MA,USA) as de-
scribed previously [18]. Briefly, purified EVs were resus-
pended in PBS supplemented with 1 μM Dil dye and
ultracentrifuged at 100,000 g for 1 h at 4 °C. Following
labeling, the EVs were washed once more with PBS by
ultracentrifugation as mentioned above. The pellet ob-
tained was then resuspended in RPMI with 1% DMSO
and frozen for subsequent studies.
Concentration and size distribution of EVs were deter-
mined by the Nanosight LM10 system (NanoSight, Wilt-
shire, UK). Briefly, EV preparations were diluted (1:200)
in sterile saline solution and analyzed by the Nanoparti-
cle Analysis System using the NTA 1.4 Analytical Soft-
ware [21].
Flow cytometric analysis
Cytofluorometric analysis was performed as described
previously [4]. The antibodies used (conjugated with
phycoerythrin (PE) or fluorescein isothiocyanate (FITC))
are as follows: anti-CD45, anti-Albumin, anti-CD90,
anti-CD73, anti-CD105, anti-CD29, anti-CD31, anti-
KDR, and anti-VE-Cadherin (Dako Denmark A/S,
Copenhagen, Denmark). All incubations with antibodies
were performed in 100 μl PBS containing 0.1% bovine
serum albumin (BSA) at 4 °C. The cells were washed
twice between incubations and analyzed (10,000 cells/
sample) on a BD FACSCalibur cytometer (BD Biosci-
ences Pharmingen, San Jose, CA, USA). For detection of
albumin, cells were permeabilized and labeled with anti-
albumin monoclonal antibody (R&D Systems, Abington,
UK) followed by PE-conjugated anti-mouse IgG second-
ary antibody. All samples were gated on the basis of
negative controls, and compensated appropriately prior
to analyses. Population percentages and numbers were
generated for gated populations from each experiment
using Cell Quest software (BD Biosciences Pharmingen).
In vitro osteogenic, adipogenic, and endothelial
differentiation
Osteogenic, adipogenic, and endothelial differentiation of
ASS1-HLSCs was performed as described previously [4].
Briefly, ASS1-HLSCs were cultured in osteogenesis induc-
tion medium (Lonza) for 3 weeks (replenished twice per
week for 3 weeks). Differentiation was evaluated by fixing
cells with 4% paraformaldehyde for 20 min and then stain-
ing with alizarin red, pH 4.1 (Sigma-Aldrich), at room
temperature. For adipogenic differentiation, cells were cul-
tured in adipogenesis induction medium (Lonza), followed
by adipogenic maintenance medium (Lonza). To evaluate
the differentiation, cells were fixed with 4% paraformalde-
hyde for 20 min at room temperature then stained with
0.5% oil red O (Sigma-Aldrich) in methanol (Sigma-Al-
drich). Endothelial cell differentiation was obtained by cul-
turing ASS1-HLSCs in EBM (Lonza) with vascular
endothelial growth factor (10 ng/ml; Sigma-Aldrich) for
10 days. Following culture, endothelial differentiation was
evaluated by flow cytometric analyses of endothelial
markers as described previously [4].
Immunofluorescence analysis
Indirect immunofluorescence of cells was performed as
described previously [4]. Briefly, ASS1-HLSCs cultured
on chamber slides (Nalge Nunc International, Rochester,
NY, USA) were fixed with 4% paraformaldehyde and/or
permeabilized (only for intracellular markers) with 0.1%
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Triton X-100 buffer. Cells were then labeled with the
following monoclonal antibodies: anti-albumin (R&D
Systems), anti-nestin (BD Biosciences Pharmingen), anti-
α-fetoprotein (αFP; R&D Systems), anti-nanog (Abcam,
Cambridge, MA), anti-Sox2 (Abcam), anti-vimentin
(Sigma-Aldrich), anti-cytokeratin 8 (CK8), anti-CK19,
anti-Von Willebrand factor (all from Sigma-Aldrich),
and anti-ASS1 (Thermo Fisher Scientific). Alexa Fluor
488 anti-rabbit IgG and Texas Red anti-mouse IgG
(Thermo Fisher Scientific) were used as secondary anti-
bodies and Hoechst 33258 dye (Sigma-Aldrich) was ap-
plied for nuclear staining. Labeling of cells with only
secondary antibodies or substitution with nonimmune
rabbit, rat, or mouse IgGs served as controls. Slides were
analyzed by confocal microscopy using a Zeiss LSM 5
Pascal Model Confocal Microscope (Carl Zeiss Inter-
national, Jena, Germany).
In vitro culture in RCCS and urea production
In order to differentiate HLSCs and ASS1-HLSCs into
functional hepatocytes, cells were cultured in microgravity
conditions using the Rotary Cell Culture System (RCCS;
Synthecon Incorporated, Houston, TX, USA) as described
previously [4]. Briefly, cells (250,000/ml) were resuspended
in medium consisting of 75% Dulbecco’s modified Eagle’s
medium (DMEM; Mediatech, Herndon, VA, USA), and
25% MCDB 201 (Sigma-Aldrich) supplemented with 2%
fetal bovine serum (FBS), linoleic acid (Sigma-Aldrich), L-
ascorbic acid (Sigma-Aldrich), insulin-transferrin-selenium
(ITS; Sigma-Aldrich), penicillin (100 μg/ml), streptomycin
(100 μg/ml), and 10 ng/ml of hepatocyte growth factor
and fibroblast growth factor 4; 10 ml of the cell suspension
was then loaded into circular RCCS vessels and rotated
about their own axis at 8–10 rotations per minute under
37 °C conditions. After 4 days of culture, the supernatant
was collected, centrifuged at 300 g for 5 min and stored at
–20 °C. Levels of urea in the supernatants were then evalu-
ated using the blood urea nitrogen (BUN) colorimetric de-
tection kit as per the manufacturer’s protocol (Arbor
assays, MI, USA). For selective RCCS experiments, cells
were cultured in the presence of HLSC-EVs with or with-
out α-methyl-DL-aspartic acid (MDLA), a specific inhibitor
of ASS1 enzyme. Treatment of ASS1-HLSCs with ASS1
shRNA EVs or fibroblast EVs (hFib EV) served as controls.
Western blot analysis
The level of ASS1 enzyme in cells was determined by
Western blot analyses. Briefly, cells were lysed on ice for
30 min in radioimmunoprecipitation assay (RIPA) buffer
(50 mM Tris-HCl PH 7.4, 150 mM NaCl, 1% NP-40,
0.1% SDS; Sigma-Aldrich) supplemented with the prote-
ase inhibitors phenylmethylsulfonyl fluoride (PMSF)
(1 mM), leupeptin (10 μg/ml), and aprotinin (100 units/
ml). Proteins from EVs were isolated using the all-in-one
purification kit (Norgen Biotek Corp, TO, Canada) ac-
cording to the manufacturer’s protocol, and the concen-
trations determined by the Bradford method.
Protein samples at a concentration of 10–30 μg were
separated in 8% or 4–15% gradient SDS-PAGE gels under
reducing conditions and electroblotted onto 0.2-mm
nitrocellulose membranes (GE Healthcare Life Sciences,
MA, USA). The membranes were blocked in Tris-
buffered saline-Tween (TBS-T; 25 mM Tris, pH 8.0,
150 mM NaCl, and 0.05% Tween-20) containing 5% (w/v)
nonfat dried milk for 1 h. After blocking, membranes were
probed overnight with mouse anti-ASS1 (BD Transduc-
tion Laboratories), mouse anti-CD63, rabbit anti-tubulin,
and goat anti-actin (Santa Cruz Biotechnology, CA, USA).
After extensive washings with TBS-T, the blots were incu-
bated with appropriate peroxidase conjugated secondary
antibodies (goat anti-mouse, goat anti-rabbit, and mouse
anti-goat IgG; Pierce, Thermo Fisher Scientific) for 1 h at
room temperature. Following incubation, the membranes
were washed extensively with TBS-T, probed with en-
hanced Super Signal West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientific), and detected by the
Chemidoc system (Bio-rad, CA, USA).
Immunoprecipitation and enzymatic activity of ASS1
Cells were lysed in nondenaturing lysis buffer (137 mM
NaCl, 2 mM EDTA, 20 mM Tris–HCl, pH 7.5, 10% gly-
cerol, 1% Nonidet P-40, and protease inhibitor cocktail)
and centrifuged at 300 g for 15 min at 4 °C. The super-
natants were collected and quantified for total protein
concentration using the Bio-Rad protein assay method.
Immunoprecipitation of ASS1 was performed using
Dynabeads Protein G (Thermo Fisher Scientific). Briefly,
the beads were incubated with 10 μg ASS1-antibody
(Thermo Fisher Scientific) per mg of total protein for
1.5 h at 4 °C to form complexes. The bead/ASS1-anti-
body complexes were washed with PBS-0.02% tween and
incubated with cell lysates (1 mg total protein) overnight
at 4 °C under rotation. After three washes with PBS-
0.02% tween, ASS1 proteins were eluted by adding 20 μl
50 mM glycine at pH 2.8. In order to prevent the loss of
the tridimensional structure of ASS1, 200 μl TRIS-HCL
20 mM pH 7.8 was added.
Eluted proteins were then evaluated for ASS1 activity
using a modified version of the assay described by
Lakhal-Naouar et al. [22]. Briefly, eluted protein samples
(12.5 μl per reaction) were resuspended in reaction buf-
fer (20 mM Tris-HCl, pH 7.8, 4 mM ATP, 4 mM citrul-
line, 4 mM aspartate, 6 mM MgCl2, 20 mM KCl, and
0.2 units of pyrophosphatase) to a final volume of 20 μl.
The reaction samples were then transferred to 96-well
microtiter plates in duplicates and incubated for 30 min
at 37 °C. Following incubation the reaction was stopped
by adding 20 μl malachite green reagent (Malachite
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Green Phosphate Assay Kit, Bioassay System, CA, USA).
Reactions without citrulline and aspartate substrates
were prepared to serve as controls. Phosphate accumula-
tion was determined at 655 nm by spectrophotometry,
and the concentration interpolated from a standard
curve of inorganic phosphate (Pi). Due to the spontan-
eous release of Pi in the absence of substrates, the final
concentration of Pi from affinity-purified proteins and/
or rat liver extract (RLE; served as positive control for
the reaction) were determined by subtracting the mean
concentration of Pi obtained in the absence of substrates
from the mean concentration of Pi obtained in the pres-
ence of substrates. The specific ASS1 activity was deter-
mined using the following formula: nanomoles of
phosphates released/mg protein/30 min [22]. In selected
experiments, ASS1-siRNA transfected ASS1-HLSC were
used.
RNA extraction and qRT-PCR
Total RNA from cells was extracted using TRIzol re-
agent (Thermo Fisher Scientific) and total RNA from
HLSC-EVs was isolated using the all-in-one purification
kit (Norgen Biotek Corp.) according to the manufac-
turer’s protocol. The quantity and quality of isolated
RNAs were determined using the Nanodrop ND-1000
spectrophotometer (Thermo Fisher Scientific). cDNA
was then synthesized using the High Capacity cDNA Re-
verse Transcription Kit (Thermo Fisher Scientific) as per
the manufacturer’s protocol. cDNA at a concentration of
2 ng was used per sample per quantitative real-time poly-
merase chain reaction (qRT-PCR) reaction in triplicate
using a 96-well StepOne Real-Time System (Thermo
Fisher Scientific). Wells containing only primers were cy-
cled in parallel with each run and served as negative
cDNA controls. For mRNA expression in cells, results
were analyzed using the RQ method with GUSB gene as
an internal control and for HLSC-EVs, the 2–ΔCt method
was adopted using S18 gene as internal control. Primers
and probes were designed using the Universal ProbeLi-
brary Assay Design Center software (www. lifescience.ro-
che.com). Primers used to amplify ASS1 mRNAs are
summarized in Table 1.
ASS1 silencing
A set of five pLKO.1 HIV-based lentiviral vectors targeting
the human ASS1 gene were purchased (TRCN0000045553,
TRCN0000045554, TRCN0000045555, TRCN0000045556,
TRCN0000045557; Dharmacon RNAi Consortium (TRC)
Lentiviral shRNA). shRNAs were tested on HLSCs to
evaluate the silencing efficiency and the most efficient and
stable shRNA was used to specifically downregulate ASS1
expression in HLSCs. The lentiviruses pLKO.1-scr (ex-
pressing a “scramble” shRNA as control) and pLKO.1-
ASS1 (expressing the shRNA specific for ASS1) were
produced in HEK293FT cells using a lentiviral packaging
system after which HLSCs were infected with the lentivi-
ruses in the presence of Sequa-brene (Sigma-Aldrich).
Following infection, cells were selected with 5 μg/ml puro-
mycin. The efficacy and stability of silencing in selected
cells was evaluated by qRT-PCR.
siRNA transfection
ASS-siRNA and nonsilencing siRNA were purchased
from Thermo Fisher Scientific. Transient transfection
of ASS-siRNA was performed using Lipofectamine
RNAiMAX transfection reagent (Invitrogen) as per
the manufacturer’s protocol. ASS1-HLSCs (500,000
cells per well) were seeded in a petri dish (10-cm
diameter) and cultured for 24 h. The complete
culture medium was replaced with antibiotic-free
medium and transfected with 300 pM ASS-siRNA or
nonsilencing RNA for 3 days in the presence of Lipo-
fectamine RNAiMAX. Before the addition in cell cul-
tures, siRNAs were incubated with lipofectamine for
20 min at room temperature in Opti-Mem medium
(Invitrogen). Preliminary experiments using FITC-
siRNA (Qiagen, Valencia, CA, USA) indicated that
the peak of expression was 3 days after transfection.
After 3 days of transfection, ASS1-HLSCs were de-
tached with trypsin and 3.0 × 106 cells were cultured
in RCCSs in the presence of 1 × 1010 EV-HLSCs. The
effective ASS-siRNA transfection was evaluated in
ASS1-HLSCs by RT-PCR. ASS enzymatic activity was
measured after 4 days of culture under RCCS culture
conditions.
DNA mutation analysis
Genomic DNA was extracted using DNeasy Blood &
Tissue Kit (Qiagen) according to the manufacturer’s in-
structions. The quality and quantity of extracted DNA
was determined using the Nanodrop ND-1000 spectro-
photometer (NanoDrop Technology).
Table 1 Primers used in qRT-PCR to evaluate ASS1 mRNA
expression
PCR primers Primer sequences (5′–3′)
hASS1-Iso1 F1 TGT GAA AAC AGA TTC CACG C
R1 CCA ATG TTG GCC AGA TAG GC
hASS1-Iso2 F1 ACG CTA TGT CCA GCA AAG GC
R1 CCA ATG TTG GCC AGA TAG GC
hASS1-Exon 14 (Primer 1) F AAGTCCCAGGAGCGAGTGG
R GTGGGGCACCTACCTCACC
hASS1-Exon 15 (Primer 2) F GCCAGGCTGAGCTGACAAG
R ACCTGGAGGCTCTGAAGGC
ASS argininosuccinate synthase, F forward, qRT-PCR quantitative real-time
polymerase chain reaction, R reverse
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Two regions of the human ASS1 gene located in exons
14 and 15 were amplified by PCR. These regions com-
prise of the following codon mutations: R363W (exon
14) and G390R (exon 15). The primers were developed
(Table 2) based on the GenBank reference sequence (ac-
cession no. NC_000009.11), using Primer Express 3.0
software (Thermo Fisher Scientific). PCR was then per-
formed in a final volume of 50 μl, containing 10× PCR
buffer, 0.05 units/μl JumpStart Taq polymerase, 10 mM
deoxynucleotide triphosphates mix, 150 ng genomic
DNA, and 500 nM primers. Cycling conditions were as
follows: 1 min at 94 °C, 35 cycles at: 94 °C for 30 s, 62 °C
Table 2 SNaPshot primers
SNaPshot primers SNaPshot primer sequences
R363W T20GGTGTACATCCTCGGC
G390R T30GCCAACTGATGCCACC
R363W was used to amplify the genomic region containing the codon
mutation g.55277 C > T and primer G390R for the region containing the
mutation g.59839 G > A
Fig. 1 Characterization of ASS1-HLSCs. a Representative flow cytometric analysis of markers expressed by ASS1-HLSC (black histograms; dotted
histograms represent the isotypic controls). Cells were labeled with FITC- or PE-conjugated antibody. One hundred percent of ASS1-HLSCs were
positive for CD90, CD73, CD29, and CD105, and negative for CD45 as described previously for normal HLSCs [4]. ASS1-HLSCs were also positive
for the liver marker albumin [4]. Data represent one of three experiments with similar results. b Representative immunofluorescence micrographs
of ASS1-HLSCs stained with antibodies against albumin, nestin, α-fetoprotein (α-FP), nanog, sox2, vimentin, cytokeratin (CK)8 and CK19. Hoechst
dye 33258 was applied for nuclei staining. Scale bars = 5 μm. Data represent one of three experiments with similar results
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for 30 s, and 72 °C for 60 s, followed by 1 min at 72 °C. At
the end of the reaction, 10 μl PCR-amplified DNA sam-
ples were analyzed using 1% agarose gel.
To evaluate the presence of DNA in EVs derived from
HLSCs, DNA was extracted and analyzed by PCR.
Briefly, 14 different preparations of EVs obtained from
HLSCs were pooled together by ultracentrifugation at
100,000 g for 2 h at 4 °C. The supernatant was discarded
and lysis buffer was added directly to the EV pellet and
processed as per the manufacturer’s protocol to isolate
the DNA (DNeasy Blood & Tissue Kit, Qiagen). Exons
14 and 15 of the hASS1 gene were amplified using PCR
as described above and amplicons were analyzed using
1% agarose gel.
PCR products from ASS1-HLSCs and ASS1-HLSCs
treated with HLSC-EVs were analyzed for mutations
(c.1087C > T and c.168G > A) using the ABI PRISM
SNaPshot Multiplex Kit (Thermo Fisher Scientific), ac-
cording to the protocol supplied by the manufacturer
(normal HLSCs served as control). The SNaPshot
method is based on the dideoxy single-base extension
of unlabeled oligonucleotide primers. For each of the
two mutations analyzed above, a primer annealing adja-
cent to the potentially mutant nucleotide was devel-
oped (Table 2). Briefly, the SNaPshot reaction was
performed in a volume of 10 μl, containing 3 μl PCR
product, 5 μl ready reaction mix, 1× sequencing buffer,
and SNaPshot primers concentrated at 0.02 pmol/μl. At
the end of the reaction, the labeled products were first
treated with shrimp alkaline phosphatase (SAP; USB
Corporation) to remove excess dideoxynucleotide tri-
phosphate and then separated on 36-cm-long capillaries
by performing a 25-min run in an automatic sequencer
(ABI PRISM 3500 Genetic Analyzer, Thermo Fisher
Scientific). GeneScan Analysis Software version 3.7
(Thermo Fisher Scientific) was used for data analysis.
For each sample, the intensity of the fluorescent peak
was measured.
Fig. 2 The expression of ASS1 gene and ASS1 mRNA in HLSCs and ASS1-HLSC. a,b Representative SNaPshot sequences of ASS1 gene in normal
human liver stem cells (HLSCs) and HLSCs from the liver of a patient suffering from citrullinemia type 1 (ASS1-HLSCs). a The upper electropherogram
shows a normal ASS1 gene profile from HLSCs; the lower electropherogram shows the mutated gene profile from ASS1-HLSCs (c.1087C > T). b The
upper electropherogram shows a normal ASS1 gene profile; the lower electropherogram shows the mutated ASS1-HLSC gene profile (c.168G> A).
Data represent one of three experiments with similar results. c qRT-PCR analysis showing the expression of ASS1 isoforms 1 (Iso1) and 2 (Iso2) mRNA in
human hepatocytes (hH), HLSCs, and ASS1-HLSCs. hH were used as positive control. d qRT-PCR analysis of ASS1 Iso1 mRNA in HLSCs transfected with
ASS1 shRNA. Data represent the mean of two independent experiments performed in triplicate. *p < 0.05, HLSC shRNA-ASS1 vs HLSC Ctrl-SCR. A
adenine, C cytosine, F.U fluorescence unit, G guanine, SCR scramble, T thymine
Herrera Sanchez et al. Stem Cell Research & Therapy  (2017) 8:176 Page 7 of 15
Statistical analysis
Results are expressed as mean ± standard deviation (SD).
Statistical analysis was performed using the Student’s t
test and analysis of variance (ANOVA) with Newmann-
Keuls test or ANOVA with Dunnet’s multicomparison
tests where appropriate. A p value <0.05 was considered
significant.
Results
Characterization and in vitro differentiation of
citrullinemia type I-derived ASS1-HLSCs
ASS1-HLSCs derived from the liver of a patient with
citrullinemia type I were characterized to confirm their
expression of stem cell markers similar to HLSCs. Flow
cytometric analysis revealed that ASS1-HLSCs, like their
normal counterparts, were positive for several mesenchy-
mal stem cell markers such as CD90, CD73, CD29, and
CD105 (Fig. 1a). Furthermore, they were positive for the
liver tissue-specific marker albumin but negative for the
hematopoietic marker CD45 (Fig. 1a). In addition, im-
munofluorescence microscopy confirmed ASS1-HLSCs to
be positive for the hepatocyte precursor marker α-FP, as
well as vimentin (100%), nestin (100%), and CK8 (40%)
(Fig. 1b). In contrast, CK19, a marker for oval cells, was
negative (Fig. 1b). To assess the in vitro differentiation
capabilities of ASS1-HLSCs, they were induced to differ-
entiate into endothelial, osteogenic, and adipogenic
lineages. Similar to HLSCs, ASS1-HLSCs were able to
undergo endothelial differentiation when cultured in
endothelial induction medium (Additional file 1: Figure
S1). After 3 weeks in culture, ASS1-HLSCs compared to
undifferentiated cells expressed de novo endothelial
markers such as KDR, CD31, VE-cadherin, and von Will-
ebrand Factor (vWF). Furthermore, when cultured in
osteogenic differentiation medium, ASS1-HLSCs trans-
formed morphologically from spindle shaped cells to cu-
boidal cells and underwent mineralization as reflected by
alizarin staining (Additional file 1: Figure S1). ASS1-
HLSCs when maintained in adipogenic differentiation
medium did not differentiate into adipocytes as was also
observed with normal HLSCs (data not shown).
In order to identify and characterize the ASS1 mu-
tations in ASS1-HLSCs, a SNaPshot sequencing ana-
lysis was implemented. Briefly, after DNA extraction,
a first amplification step was performed using two
different specific primers for the genomic regions of
the ASS1 gene expressing two potential codon muta-
tions (g.55277 C > T, g.59839 G > A). The PCR prod-
ucts were then analyzed for mutations using the ABI
PRISM SNaPshot Multiplex Kit. As shown in Fig. 2a
and b, the mutations in ASS1-HLSCs were confirmed
by the presence of the mutated bases T and A which
were absent in normal HLSCs. At variance to mature
hH that expressed both isoform 1 and 2 of ASS1
Fig. 3 The expression of ASS1 protein in HLSCs and ASS1-HLSCs. a Western blot confirming the presence or absence of ASS1 protein isoform 1
(Iso1) and isoform 2 (Iso2) in 10 μg total protein extracted from human hepatocytes (hH), human liver stem cells (HLSCs), HLSCs from the liver of a
patient suffering from citrullinemia type 1 (ASS1-HLSCs), and Rotary Cell Culture System (RCCS)-differentiated HLSCs and ASS1-HLSCs. Actin was
run on a parallel gel as a representative of loading. b Quantification of the relative band intensity of ASS1 Iso1 across all samples in Fig. 3a
normalized to actin. c Representative immunofluorescence micrographs of hH, HLSCs, ASS1-HLSCs, and RCCS-differentiated HLSCs and ASS1-HLSCs
stained for ASS1 enzyme. The nuclei of the cells were stained with Hoechst dye 33258. Original magnification × 400, scale bar = 50 μm. Data represent
one of two experiments with similar results. d Quantification of the relative fluorescence intensity (RFI) of all the cell culture conditions in Fig. 3c with
hH serving as a positive control established as the 100%. Data represent the mean of three independent experiments with similar results. §p < 0.05,
HLSCs/RCCS vs HLSC; ^p < 0.05, ASS1-HLSC/RCCS vs ASS1-HLSC; *p < 0.05, HLSC/RCCS vs HLSC; #p < 0.05, ASS1-HLSC/RCCS vs ASS1-HLSC
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mRNA, the undifferentiated HLSCs and ASS1-HLSCs
expressed mainly isoform 1 (Fig. 2c). Figure 2d shows
the reduction of ASS1 mRNA expression in HLSCs
silenced for the ASS1 gene.
Expression of ASS1 protein
The expression of ASS1 protein in mature hH, HLSCs,
and ASS1-HLSCs was evaluated by Western blot (Fig. 3a
and b). hH expressed two isoforms of ASS1 protein, one
Fig. 4 Characterization of HLSC-derived EVs. a Representative Western blot analysis of ASS1 and CD63 expression in human liver stem cells
(HLSCs) and the 10 K and 100 K fractions of HLSC-derived extracellular vesicles (EVs) obtained by differential ultracentrifugation. Tubulin was run
on a parallel gel as a representative of loading (10 μg protein). Data represent one of two experiments with similar results. b Flow cytometric
analysis of mesenchymal stem cell markers expressed by the 100 K fraction of HLSC-EVs. The 10 K fraction also expresses mesenchymal stem cell
markers (data not shown). Data represent one of two experiments with similar results. c NanoSight quantification of HLSC-EVs obtained from the
100 K fraction before and after floating separation on iodixanol gradients (data represent a mean of three different experiments). Insert: representative
electron microscopy of 100 K fraction of HLSC-EVs (scale bar= 100 nm). d NanoSight size distribution graph showing the quantity and size of HLSC-EVs
obtained from the 15% iodixanol gradient. e Representative Western blot analysis of CD63 and ASS1 protein expression in HLSC-EVs isolated from
different iodixanol fractions. Data represent one of two experiments with similar results. f Expression levels of ASS1 isofrom 1 (Iso1) and isoform 2 (Iso2)
mRNA in 100 K HLSC-EVs. g Expression levels of ASS1 Iso1 mRNA in EVs isolated from different iodixanol fractions. h ASS1 mRNA Iso1 expression in EVs
derived from ASS1 shRNA transfected HLSCs compared with EVs derived from HLSCs transfected with the scramble (SCR). Insert: representative Western
blot analysis of ASS1 protein expression in EVs isolated from shRNA transfected HLSCs (EV shRNA-ASS1) and from EVs isolated from HLSCs transfected
with the scramble shRNA (EV Ctrl-SCR). Data represent the mean of three independent experiments performed in triplicate. #p < 0.05, EV shRNA-ASS1 vs
EV Ctrl-ASS1
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at 46 kDa (isoform 1 (Iso1)) and the other at 40 kDa
(isoform 2 (Iso2)) (Fig. 3a). Consistent with the low ex-
pression of Iso2 mRNA in undifferentiated HLSCs and
ASS1-HLSCs, Western blot analysis showed only Iso1.
This suggests that under undifferentiating conditions the
low amount of Iso2 mRNA was not translated into pro-
tein. However, differentiation into hepatocytes via RCCS
induced the expression of the Iso2 for both HLSCs and
ASS1-HLSCs (Fig. 3a). Moreover, after differentiation
the expression of Iso1 was increased in both HLSCs and
ASS1-HLSCs compared to the undifferentiated counter-
parts (Fig. 3a and b).
The expression of the ASS1 protein in hH, HLSCs,
and ASS1-HLSCs was further confirmed by immuno-
fluorescence staining (Fig. 3c). As seen in Fig. 3d, quanti-
tative analysis of ASS1 protein expression shows a
significant increase after RCCS-induced differentiation
(Fig. 3c and d). These data therefore confirm that differ-
entiation to hepatocytes of both the wild-type and mu-
tated HLSCs significantly increases the expression of the
ASS1 protein.
Characterization of HLSC-EVs
On analyzing the 10 K and 100 K fractions, ASS1 pro-
tein expression was observed only in the 100 K fraction
concurrently with the expression of the exosomal
marker CD63 (Fig. 4a). Furthermore, the same fraction
was also positive for the mesenchymal markers typical of
HLSCs as observed by fluorescence-activated cell sorting
(FACS) analysis (Fig. 4b). No further analysis was
performed on the 10 K fraction as it was negative for
ASS1 and CD63 (Fig. 4a).
The 100 K fraction was also submitted to floating sep-
aration whereby 75% of the EVs were detected in the
15% iodixanol fraction with a mean size of 155 ± 3.6 nm
as determined by NanoSight analysis (Fig. 4c and d). In
addition, transmission electron microscopy revealed a
homogenous layer of these vesicles with a morphology
resembling exosomes with a smaller size than observed
by NanoSight (Fig. 4c, insert). Furthermore, on analyzing
the EVs obtained from the three iodixanol fractions by
Western blot, only the 15% fraction was positive for the
exosomal marker CD63 as well as the ASS1 protein
(Fig. 4e).
PCR analysis also confirmed at a molecular level the
presence of mRNA for ASS1 Iso1 but not for ASS1 Iso2
in 100 K HLSC-EVs (Fig. 4f ) and in the 15% iodixanol
EV fraction compared to the other fractions (Fig. 4g).
In order to evaluate whether restoration of ASS1 en-
zymatic activity was observed in ASS1-HLSCs treated
with HLSC-EVs, we generated EVs depleted of the ASS1
enzyme by silencing the gene at a cellular level. As
shown in Fig. 4h, EVs derived from HLSC shRNA-ASS1
were depleted of both Iso1 ASS1 mRNA and protein.
EVs derived from normal HLSCs increased urea production
and ASS1 enzymatic activity in mutated ASS1-HLSCs
As shown in Fig. 5, HLSC-EVs were internalized in
ASS1-HLSCs after 6 h of incubation at 37 °C. It has
been described that, as a consequence of the genetic
mutations, the ASS1 enzyme activity is decreased in
Fig. 5 Internalization of HLSC-EVs in hepatocytes differentiated from ASS1-HLSCs. Representative confocal microscopy showing the internalization
of 1 × 1010 Dil-labeled EVs in hepatocytes differentiated from ASS1-HLSCs after 6 h of incubation at 37 °C. Z stack analysis shows the presence of
EVs within the cytoplasm of the cells indicating an effective uptake of vesicles; scale bar = 50 μm. Data represent one of three experiments per-
formed with similar results
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fibroblasts, liver, and in all ASS1-expressing tissues [2].
In order to evaluate whether HLSC-EVs were able to
correct the defective urea production and enzymatic ac-
tivity in ASS1-HLSCs, ASS1-HLSCs were treated with
HLSC-EVs (1 × 1010 particles) in RCCS for 4 days. At
the end of the experiments, urea production and ASS
enzymatic activity were measured (Fig. 6a and b).
Mutated ASS1-HLSCs produced significantly less urea and
showed a decreased ASS1 enzymatic activity than normal
HLSCs. HLSC-EV treatment significantly increased urea
production and enzymatic activity in ASS1-HLSCs. The
specificity of the enzymatic activity reaction was confirmed
by the inhibitory effect of treating the cells with MDLA as
a specific inhibitor of the enzyme (Fig. 6b). ASS1 enzymatic
activity was also inhibited in HLSC-EV-treated ASS1-
HLSCs when the cells were transfected with ASS1-siRNA
(Fig. 6b). ASS1 shRNA-depleted HLSC-EVs were unable to
restore urea production in ASS1-HLSCs (Fig. 6a). The abil-
ity of HLSC-EVs to restore urea production was specific
since EVs obtained from human fibroblasts (hFib) which
did not contain ASS1 protein and only a low level of ASS1
mRNA (data not shown) were ineffective (Fig. 6a). More-
over, the reduction of ASS1 urea production by EVs de-
rived from hFib also depended on an inhibition of cell
differentiation in RCCS (data not shown).
HLSC-EV treatment decreased DNA mutations in ASS1-
HLSCs
Since HLSC-EVs carry fragments of ASS1 DNA (Fig. 7),
we evaluated whether they may affect the mutations
when incorporated into ASS1-HLSCs. We performed
SNaPshot sequencing to determine the contribution of
HLSC-EVs to correction of both mutations present in
ASS1-HLSCs. Figure 8 shows that the amplitude of picks
of the mutated bases T and A belonging to one allele of
the ASS1 region of ASS1-HLSCs was significantly re-
duced when cells were cultured in adhesion culture for
6, 24, and 48 h with HLSC-EVs (1 × 1010 particles).
Discussion
In the present study we demonstrated that EVs derived
from normal HLSCs increased the production of urea
and ASS1 enzymatic activity in hepatocytes differenti-
ated from HLSCs derived from a patient with Citrulline-
mia type I.
Citrullinemia type I is an inherited disorder of the urea
cycle caused by a genetic mutation in the ASS1 gene.
The absence of a functional form of ASS1 enzyme leads
to a rapid accumulation of ammonia and other toxic
substances in the blood leading to an early neonatal
death. Liver transplantation remains the only curative
treatment for this defect. However, due to limited avail-
ability of donor livers, substitute therapies are currently
being researched [23].
Recently, Syres et al. demonstrated that the accumula-
tion of cysteine in organs was decreased after the injec-
tion of mesenchymal stem cells in a cysteinotic
knockout mice model (CTNA–/–) [24]. The cells were
found in multiple organs resulting in a 90% decrease in
tissue cysteine levels, leading to the recovery of kidney
injury [24]. Nevertheless, the reduction in tissue cysteine
levels could not be attributed to mesenchymal stem cell
transdifferentiation or fusion with resident CTNA mu-
tated cells. In further studies, to explain the mechanism
Fig. 6 Urea production and ASS1 enzymatic activity. a Histogram
representing the urea production ability of hepatocytes differentiated
under RCCS conditions for 4 days from human liver stem cells (HLSCs),
HLSCs from the liver of a patient suffering from citrullinemia type 1
(ASS1-HLSCs), ASS1-HLSCs treated with 1 × 1010 HLSC-derived extracellular
vesicles (EVs), ASS1-HLSCs treated with 1 × 1010 HLSC-EVs from ASS1
shRNA transfected HLSCs (shRNA EVs) or with 1 × 1010 EVs derived from
human fibroblasts (hFib EV). Data are expressed as mean ± SD of four
different experiments. ANOVA with Newmann-Keuls multicomparison
tests was performed. *p < 0.05, ASS1-HLSC vs HLSC; #p < 0.05, ASS1-
HLSC + HLSC-EVs vs ASS1-HLSC; §p < 0.05, ASS1-HLSC + shRNA EVs vs
ASS1-HLSC + HLSC-EVs; ^p < 0.05 ASS1-HLSC + hFib EVs vs AS-HLSC +
EVs. b The enzymatic activity of ASS1 immunoprecipitated from either
rat liver extract (RLE; positive control), hepatocytes differentiated in
RCCS for 4 days from HLSCs, ASS1-HLSCs, or ASS1-HLSCs treated with
1 × 1010 HLSC-EVs were measured. For selected experiments the en-
zyme activity was measured in the presence of α-methyl-DL-aspartic
acid (MDLA), a specific inhibitor of ASS1 enzymatic activity, and using
ASS1-HLSCs previously transfected with ASS-siRNA. Data are expressed
as mean ± SD of four separate experiments. ANOVA with Newmann-
Keuls multicomparison tests was performed. *p < 0.05, HLSC +MDLA
vs HLSC; §p < 0.05, ASS1-HLSC vs HLSC; #p < 0.05, ASS1- HLSC + EVs vs
ASS1-HLSC; ^p < 0.05, ASS1- HLSC + EV/MDLA vs ASS1-HLSC + EV;
°p < 0.05, ASS1-HLSC + siRNA/EV vs ASS1-HLSC + EV
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of reduction of intralysosomal accumulation of cysteine,
Iglesias et al. used an in vitro coculture model of
CTNA–/– fibroblasts and human amniotic mesenchy-
mal stem cells [25]. They demonstrated that the uptake
of mesenchymal stem cell-derived EVs carrying wild-
type cysteinosin protein and mRNA by mutant fibro-
blasts significantly reduced the lysosomal accumulation
of cysteine in the cells. Katsuda et al. recently showed
that EVs derived from adipose mesenchymal stem cells
may transfer a functional enzyme to target cells [26]. In
addition, several studies provided evidence of effective
transfer of functional mRNA, miRNA, and DNA by
EVs [27–29].
Collectively, these works suggest that EVs could inter-
act with target cells and transfer functional protein and
nucleic acids that may modify their phenotype. In
agreement with this evidence, we found that HLSC-EVs
contained wild-type ASS1 protein, mRNA, and DNA.
Furthermore, on incubating these EVs with mutated
ASS1-HLSCs the mutated enzymatic effect was cor-
rected, restoring urea production and enzymatic activ-
ity. Undifferentiated HLSCs expressed Iso1 and, to a
significantly less extent, Iso2 mRNA, and the amount
of Iso2 protein was undetectable by Western blot ana-
lysis. Consistently, EVs secreted from undifferentiated
HLSCs contained only mRNA and protein of Iso1. In
addition, knocking down Iso1 by shRNA in HLSCs de-
pleted the levels of ASS1 mRNA and protein in the EVs
released subsequently by the cells. These EVs from
ASS1 shRNA knockdown HLSCs were unable to re-
store urea production in hepatocytes differentiated
from ASS1-HLSCs. This result suggests that the bio-
logical activity of EVs may depend on the transfer of
both functional ASS1 protein and mRNA. It is unclear
from this experiment to what extent protein/mRNA
transfer contributed to the recovery of ASS1 enzymatic
activity in ASS1-HLSCs. However, the result of the
experiment using transfection of ASS1-HLSCs with
ASS1-siRNA that shows inhibition of HLSC-EV-
induced correction of enzymatic activity suggests a pre-
dominant role of mRNA transfer.
In addition, we also found that HLSC-EVs carried frag-
ments of the nonmutated ASS1 gene and that the ampli-
tude of the peak of the bases mutated was reduced in
ASS1-HLSCs after treatment with vesicles. However, the
transfer of DNA was not relevant for the correction of
the enzyme activity in ASS1-HLSCs as EVs derived from
HLSCs silenced with ASS1 shRNA (which only dimin-
ished ASS1 mRNA levels) had a significant reduction in
their biological activity.
Further studies are required to evaluate whether the
horizontal transfer of DNA could also correct the en-
zymatic defect in the mutated cells. Nevertheless, several
studies have recently investigated the possibility of hori-
zontal transfer of DNA by EVs. For instance, Lázaro-Ibá-
ñez et al. [30] reported the presence of double-stranded
genomic DNA fragments in exosomes derived from
prostate cancer cells and suggested the transfer of onco-
genes between cancer and noncancerous cells. Fischer et
al. demonstrated the horizontal transfer of DNA genes
by EVs in recipient cells [31]. These studies suggest that
vesicles containing genomic DNA may be instrumental
in the exchange of genetic information between
eukaryotic cells and open the possibility to exploit this
mechanism for correction of genetic disorders.
The mechanisms of exosomal biogenesis and sorting
of proteins and nucleic acids are only partially known.
However, recently the mechanisms controlling specific
miRNA sorting in hepatocyte exosomes has been de-
scribed by Santangelo et al. [32]. They identified an RNA
binding protein SYNCRIP as a critical component of
miRNA accumulation within exosomes, suggesting a
Fig. 7 The expression of the ASS1 gene in HLSCs and EVs. ASS1 gene expression was determined in human liver stem cell-derived extracellular
vesicles (HLSC-EVs) by PCR analysis. Two different regions of human ASS1 (CTLN1) gene located in exons 14 and 15 were amplified by PCR with
two different primers that amplified both the regions respectively; exon 14 (Primer 1), exon 15 (Primer 2). A PCR without the presence of nucleotides
was used as negative control (–C). Three different preparations of EVs (lanes 2, 3, and 4 and lanes 6, 7, and 8) were analyzed in comparison with the
cells of origin (HLSCs; lanes 1 and 5)
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possible selective modulation of exosome cargo. EVs are
enriched in ribonucleoproteins that may be involved in
the storage, traffic, and protection of degradation of
ribonucleic acid [33]. Moreover, the association of Alix,
a component of endosomal sorting complex required for
transport, with Ago2, which is involved in miRNA mat-
uration, has been shown to contribute to miRNA accu-
mulation into EVs [34].
Conclusions
EVs derived from stem cells may act as paracrine me-
diators by transferring proteins and nucleic acids in-
ducing epigenetic changes in recipient cells. Herein,
we found that EVs derived from normal HLSCs have
the potential to correct ASS1 enzyme deficiency in
hepatocytes differentiated from HLSCs derived from a
patient with citrullinemia type I, suggesting a poten-
tial application of EVs derived from stem cells in
some inherited diseases.
Additional file
Additional file 1: Figure S1. In vitro differentiation of ASS1-HLSCs. (A)
Representative flow cytometric analysis of undifferentiated ASS1-HLSCs
showing negative expression of KDR, CD31, and VE-Cadherin. Von Willebrand
factor (vWF) expression and alizarin red staining for mineralization was also
Fig. 8 ASS1 mutations. a,b SNaPshot method was used to characterize the mutations in human liver stem cells (HLSCs) from the liver of a patient suffering
from citrullinemia type 1 (ASS1-HLSCs). ASS1-HLSCs were treated with 1 × 1010 HLSC-derived extracellular vesicles (EVs) in adherence culture conditions for 6,
24, and 48 h. At the end of the experiments, DNA was recovered from ASS1-HLSCs treated with or without EVs and sequencing mutation experiments
were performed to detect C-T mutations (a) and G-A mutations (b). Data are expressed as mean ± SD of three individual experiments. ANOVA with Dunet’s
multicomparison tests was performed. *p< 0.05, all experimental conditions vs ASS1-HLSC. c–d Representative electropherograms of ASS1-HLSCs
performed to detect C-T mutation (c) and G-A mutation (d). e-f Representative electropherograms of ASS1-HLSCs treated for 6 h with 1 × 1010 HLSC-EVs
showing the reduction of C-T mutation (e) and G-A mutation (f). A adenine, C cytosine, F.U fluorescence unit, G guanine, T thymine
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negative in undifferentiated conditions as observed by microscopy.
(B) Representative flow cytometric analysis of ASS1-HLSCs after endothelial
differentiation showing the presence of KDR, CD31, and VE-Cadherin (black
histograms; dotted histograms represent isotypic controls). Representative
micrographs showing the expression of vWF in ASS1-HLSCs after endothelial
differentiation, and osteogenic differentiation of ASS1-HLSCs showing positive
staining for calcium deposits as indicated by alizarin 21 days after culturing in
osteogenic differentiation medium. Scale bar = 50 μm. Data represent one of
three experiments performed with similar results. (TIF 8299 kb)
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